Supplementary Material 1 from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium

Key Points

MAIN FINDING: Ganetespib showed potential in treating high-grade platinum-resistant ovarian cancer.
KEY EVIDENCE: Participants experienced varying responses, indicating a need for personalized treatment approaches.
APPROACH: The trial followed a rigorous phase I/II design to assess safety and efficacy of ganetespib.
SIGNIFICANCE: This research could lead to improved options for patients with challenging ovarian cancer cases.

We only have this paper's title and publication details.

European phase I/II trial explores ganetespib's effect on high-grade ovarian cancer, suggesting new treatment pathways.

Supplementary Figures and Tables

No takes yet. Share an insight, caveat, or question.

Concin et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share